|
Wed, 11/04/2020 - 12:07 |
Mozambique: Urgent assistance needed for hundreds of thousands of people displaced by violence |
Doctors Without... |
|
Wed, 03/25/2020 - 07:55 |
ENHERTU Approved in Japan for Treatment of Patients with HER2 Positive Unresectable or Metastatic Breast Cancer |
Daiichi Sankyo |
|
Wed, 01/08/2020 - 21:11 |
Blueprint Medicines Announces FDA Approval of AYVAKIT (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor |
Blueprint Medicines |
|
Thu, 06/27/2019 - 13:18 |
Combination regimen reduced the risk of disease progression or death by 44 percent in newly diagnosed patients who are transplant ineligible |
Johnson and Johnson |
|
Thu, 06/20/2019 - 18:08 |
Treatment for common cause of diarrhea more promising |
Washington Univ... |
|
Mon, 03/25/2019 - 17:08 |
Widely Used Public Health Surveys May Underestimate Global Burden of Childhood Diarrhea |
JHSPH |
|
Fri, 12/21/2018 - 04:11 |
Novartis receives European Commission (EC) approval for expanded indication for Kisqali (ribociclib) |
Novartis |
|
Thu, 12/20/2018 - 14:24 |
Astellas and Pfizer Announce Positive Top-Line Results from Phase 3 ARCHES Trial of XTANDI (enzalutamide) in Men with Metastatic Hormone-Sensitive Prostate Cancer |
Pfizer |
|
Thu, 12/20/2018 - 08:09 |
Bd Completes Molecular Portfolio For GI Infection With New Viral Panel |
bd |
|
Thu, 12/20/2018 - 04:15 |
Lexicon Pharmaceuticals Announces Topline Phase 1 Clinical Results for LX2761 in Diabetes |
Lexicon Pharmac... |
|
Thu, 12/20/2018 - 03:42 |
LYNPARZA (olaparib) Meets Primary Endpoint in Phase 3 SOLO-3 Trial for the Treatment of Relapsed BRCA-Mutated Advanced Ovarian Cancer |
Cubist Pharmace... |
|
Wed, 12/19/2018 - 04:35 |
LYNPARZA (olaparib) Approved by FDA for First-Line Maintenance Therapy in BRCA-Mutated Advanced Ovarian Cancer |
Cubist Pharmace... |
|
Sun, 12/16/2018 - 22:48 |
Spectrum Health GREAT MOMS Program receives grant from Blue Cross Blue Shield of Michigan Foundation |
Spectrum Health |
|
Thu, 12/13/2018 - 10:44 |
Health Canada Grants Market Authorization for ORKAMBI (lumacaftor/ivacaftor) for Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease |
Vertex |
|
Wed, 12/12/2018 - 07:38 |
Bayer Animal Health and ParaTheraTech sign global license agreement |
bayer |
|
Sat, 12/08/2018 - 01:30 |
Novartis data demonstrates consistent efficacy and tolerability of Kisqali combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease |
Novartis |
|
Thu, 12/06/2018 - 22:34 |
Oxybutynin Decreased Frequency of Hot Flashes, Improved Quality of Life for Breast Cancer Survivors |
American Associ... |
|
Thu, 12/06/2018 - 08:56 |
Novartis investigational BYL719 (alpelisib) plus fulvestrant consistently improved PFS in patients with PIK3CA mutated HR+/HER2- advanced breast cancer in new SOLAR-1 analyses |
Novartis |
|
Wed, 12/05/2018 - 21:58 |
Liquid Biopsies in SOLAR-1 Trial Predict Benefit of Alpelisib in PIK3CA-Mutant Breast Cancer |
American Associ... |
|
Wed, 12/05/2018 - 21:55 |
FDA Approves Genentechs Tecentriq in Combination With Avastin and Chemotherapy for the Initial Treatment of People With a Specific Type of Metastatic Lung Cancer |
Genentech |
|
Wed, 12/05/2018 - 20:04 |
International Medical Corps in Yemen |
IMC |
|
Mon, 12/03/2018 - 20:55 |
FDA Grants Priority Review to Genentechs Tecentriq in Combination With Chemotherapy for the Initial Treatment of Extensive-Stage Small Cell Lung Cancer |
Genentech |
|
Mon, 12/03/2018 - 16:34 |
Comprehensive Positive Phase 3 Data for Alexions ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria Presented at American Society of Hematology (ASH) Annual Meeting and Published in Blood |
Alexion |
|
Mon, 12/03/2018 - 06:22 |
Agios Announces Updated Data from Phase 1 Study of Ivosidenib or Enasidenib in Combination with Standard Induction and Consolidation Chemotherapy in Newly Diagnosed AML Patients With an IDH Mutation |
Agios Pharmaceu... |
|
Mon, 12/03/2018 - 02:33 |
ASH 2018 Day 3: Novel Proteasome Inhibitors Update |
MMRF |
